Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06273176 · ClinicalTrials.gov registry record
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
A clinical trial of Glioblastoma and Recurrent Glioblastoma, sponsored by Erasmus Medical Center.
- Recruiting
- Registry status
- 225
- Enrollment target
- 8
- Study locations
NCT06273176: Recruiting study of Glioblastoma and Recurrent Glioblastoma, sponsored by Erasmus Medical Center.
NCT06273176 is a study of Glioblastoma and Recurrent Glioblastoma that is actively recruiting participants, run by Erasmus Medical Center. The registered enrollment target is 225 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (108% higher). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06273176, a study of Glioblastoma and Recurrent Glioblastoma, is actively recruiting participants, sponsored by Erasmus Medical Center.
- RECRUITING
- Registry status
- 225 participants
- Enrollment target
- 8
- Study locations
Study Summary
Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous evidence suggests that these techniques are beneficial for maximum safe resection in newly diagnosed grade 2-4 astrocytoma, grade 2-3 oligodendroglioma, and recently, glioblastoma. However, their effects in recurrent glioblastoma are still poorly understood. The aim of this study, therefore, is to compare the effects of awake mapping and asleep mapping with no mapping in resections for recurrent glioblastoma. This study is an international, multicenter, prospective 3-arm cohort study of observational nature. Recurrent glioblastoma patients will be operated with mapping or no mapping techniques with a 1:1 ratio. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months after surgery and 2) residual tumor volume of the contrast-enhancing and non-contrast-enhancing part as assessed by a neuroradiologist on postoperative contrast MRI scans. Secondary endpoints are: 1) overall survival (OS), 2) progression-free survival (PFS), 4) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. The study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM).
Primary Outcome
Residual tumor volume of the contrast-enhancing and non-contrast enhancing part, as assessed by a neuroradiologist on postoperative MRI scan (T1 with contrast and FLAIR sequences) using manual or semi-automatic volumetric analyses (Brainlab Elements iPlan CMF Segmentation, Brainlab AG, Munich, Germany; or similar software)
Conditions Studied
Interventions
- PROCEDURE Awake mapping under local anesthesia
- PROCEDURE Asleep mapping under general anesthesia
- PROCEDURE Resection under general anesthesia without mapping
Study Locations (8)
Other
- University Hospital Leuven - Leuven
- Universitätsklinikum Heidelberg - Heidelberg
- Technical University Munich - Munich
- Haaglanden Medical Center - The Hague
- Inselspital Universitätsspital Bern - Bern
California
- University of California, San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
South Holland
- Erasmus Medical Center - Rotterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2028-01-01 |
What NCT06273176 shows while recruiting
NCT06273176 is an observational study that tracks outcomes without assigning an intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (108% higher).
The record links to 9 conditions, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Awake mapping under local anesthesia is the first listed.
NCT06273176 lists 8 locations in 4 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06273176 about?
NCT06273176 is a clinical study titled "The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma". Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous evi...
What is the current status of trial NCT06273176?
This trial is currently recruiting. The enrollment target is 225 participants. The study started on 2023-01-01. Estimated completion is 2028-01-01.
What conditions does trial NCT06273176 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Glioblastoma, IDH-wildtype, Brain Neoplasms, Glioblastoma Multiforme of Brain.
What interventions are being tested in trial NCT06273176?
The interventions under investigation include: Awake mapping under local anesthesia (PROCEDURE), Asleep mapping under general anesthesia (PROCEDURE), Resection under general anesthesia without mapping (PROCEDURE).
Who is sponsoring clinical trial NCT06273176?
This trial is sponsored by Erasmus Medical Center, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06273176 being conducted?
This trial has 8 study locations across California, Massachusetts, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06273176's enrollment target sits among peer trials
225 24th of 199 higher than 176 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
RECRUITING
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI